MedTrace Logo

Bupivacaine in the Treatment of Postoperative Pain of Impacted Third Molar Extraction

NCT03950700 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-05-18

No results posted yet for this study

Summary

The third molars are the teeth that are most frequently included and impacted, extraction is one of the most performed treatments by maxillofacial surgeons in their clinical practice. Its surgical extraction is accompanied by an inflammatory process, which generates pain, edema and trismus. The use of alternatives that offer prolonged analgesia, like the use of bupivacaine, reduce the pain of the patient after an extraction of third molars, allows the reduction of morbidity and the rapid return to daily activities.

In addition, it allows a better experience in the dental consultation.

Investigators hypothesis is:

Irrigation of the alveolus with 4 ml of 0.5% bupivacaine is effective for the reduction of post-operative pain in extraction of impacted lower third molars

Conditions

  • Teeth, Impacted

Interventions

DRUG

Bupivacaine-epinephrine

BUPIROP® 0.5% ROPSOHN THERAPEUTICS S.A.S

DRUG

Saline Solution

Saline solution 0.9% (Baxter laboratories).

Sponsors & Collaborators

  • CES University

    lead OTHER

Principal Investigators

  • Pablo Emilio Correa Echeverri · CES University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2019-12-31
Completion
2020-01-01

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03950700 on ClinicalTrials.gov